Testosterone supplementation therapy as a treatment of hypogonadism

Bratislava Medical Journal

Volumn 110, Issue 12, 2009, Pages 765-772

  Schmidtova, E ^a   Kelemenova, S ^a   Ostatnikova, D ^a  

^a Bratislava   (Slovakia)

Author keywords

ADAM; AMS; Androgen receptor; Andropause; Anging of men; AR gene; Hypogonadism; PADAM; Supplementation; Testosterone; Testosterone Replacement therapy

Indexed keywords

TESTOSTERONE;

AGED; AGING; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MALE; METABOLISM; MIDDLE AGED; REVIEW;

AGED; AGING; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; TESTOSTERONE;

EID: 77952984824     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Harman SM et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Anging. J Clin Endocrinol Metab 2001; 86: 724-731.
2. Vermuelen A. Andropause. Maturitas-Europ Menopause J 2000; 34: 5-15.
3. Gruenewald DA, Matsumoto AM. Testosterone Supplementation Therapy for Older Men: Potential Benefits and Risks. Progress Geriat 2003; 51: 101-115.
4. Hollander N, Hollander VT. The microdetermination of testostero ne in human spermatic vein blood. J Clin Endocrinol Metab 1958; 18: 966-971.
5. Matsumoto AM. Andropause: Clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 2002; 57: M76-99.
6. Xiong G, Maser E. Regulation of the steroid-inducible 3alpha-hydroxysteroid dehydrogenase/carbonyl reductase gene in Comamonas testosteroni. J Biol Chem 2001; 276: 9961-9970.
7. Morley JE et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46: 410-413.
8. Feldman HA et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87: 589-598.
9. Haren M et al. The calculation of bioavailable testosterone. In: Robaire B, Chemes H, Morales C (Eds). Proceedings of the VII International Congress of Andrology. Englewood, NJ: Medimond. 2001: 209-221.
10. Morley JE, Perry III HM. Andropause: An old concept in new clothing. Clinics in Geriatric Medicine. 2003; 19: 507-528.
11. Moilanen AM et al. Activation of androgen receptor function by a novel nuclear protein kinase. Mol Biol Cell 1998; 9: 2527-2543.
12. Benten WP et al. Testosterone signaling through internalizable surface receptors in androgen receptor-free macrophages. Mol Biol Cell 1999; 10: 3113-3123.
13. Ramirez VD, Zheng J. Membrane sex-steroid receptors in the brain. Front Neuroendocrinol 1996; 17: 402-439.
14. Hiipakka A, Liao S. Molecular mechanism of androgen action. TEM 1998; 9: 317-324.
15. Simpson E et al. The role of local estrogen biosynthesis in males and females. TEM 2000; 11: 184-188.
16. Williams CL, Barnett AM, Meek WH. Organizational effects of early gonadal secretions on sexual differentiation in spatial memory. Behav Neurosci 1990; 104: 84-97.
17. McKinlay JD, Feldman MA. Age related variation in sexual activity and interest in normla men: Results of the massachussets Male Anging Study. In: Rossi AJ (Ed). Sexuality across the Life Course. Chicago, IL: The University of Chicago Press; 1994: 213-236.
18. Baumgartner RN et al. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999; 107: 123-136.
19. Roy TA et al. Interrelationships of serum testosterone and free tes tosterone index with FFM and strenght in ageing men. Amer J Physiol Endocrinol Metab 2002; 283: E284-294.
20. Zgliczynski S et al. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 1996; 121:35-43.
21. Wittert GA et al. Low dose oral testosterone supplementation in creased muscle and decrease fat mass in healthy alederly males with low-normal gonadal status. J Clin Endocrinol Metab 2003.
22. Yuan-Shan Zhu. Molecular Basis of Steroid Action in the Prostate. Cellscience Review, 2005; 4.
23. Quigley CA et al. Androgen receptor defects: Historical, clinical, and molecular perspectives. Endocr Rev 1995; 16: 271-321.
24. Heinlein CA, Chang C. Androgen receptor (AR) co-regulators: An overview. Endocrinol Rev 2002; 23: 175-200.
25. La Spada AR et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352: 77-79.
26. Mikuma N et al. Role of the hypothalamic opioidergic system in the control of gonadotropin secretion in elderly men. Andrologia 1994; 26: 39-45.
27. Hsing AW et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: A population-based case-control study in China. Cancer Res 2000; 60: 5111-5116.
28. Chamberlain NL, Driver ED, Miesfeld RL. The length and loca tion of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994; 22: 3181-3186.
29. Freedman LP. Anatomy of the steroid receptor zinc finger region. Endocrinol Rev 1992; 13: 129-145.
30. Matias PM et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000; 275: 26164-26171.
31. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev 2001; 81: 1269-1304.
32. Chang CY, McDonnell DP. Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol 2002; 16: 647-660.
33. Meikle AW et al. Quantitating genetic and non genetic factors to determine sex steroid variation in normal male twins. Acta Endocrinol 1675; 80: 723-743.
34. Leder BZ et al. Effects of Aromatase Inhibitions in Elderly Men with Low or Borderline-Low Serum Testosterone Levels. J Clin Endocrinol Metabo 2004; 89: 1174-1180.
35. Burris AS et al. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadalmen. J Androl 1992; 13: 297-304.
36. Alexander GM et al. Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Horm Behav. 1998; 33: 85-94.
37. Christiansen K. Behavioural correlates of testosterone. In: Nieschlag S (Ed). Testosterone: Action, deficiency, substitution. 2nd ed. Berlin: Springer 1998: 107-142.
38. Bhasin S, Bross R, Storer TRC. Androgens and muscles In: Nie schlag S (Ed). Testosterone: Action, deficiency, substitution. 2nd ed. Berlin: Springer 1998: 209-227.
39. Finklestein JS. Androgens and bone metabolism. In: Nieschlag S (Ed). Testosterone: Action, deficiency, substitution. 2nded. Berlin: Springer 1998: 187-207
40. English KM et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur. Heart J 2000; 21: 890-894.
41. Kaufman JM, Vermuelen A. Androgens in male senescence. In: Nieschlag S (Ed). Testosterone: Action, deficiency, substitution. 2nd ed. Berlin: Springer 1998: 437-471.
42. Khosla S et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86: 3555-3561.
43. Harman SM, Tsitouras PD. Reproductive hormones in aging men. I. Measurement of sex steroids basal luteinizing hormone, and Leydig's cell response to human chorionic gonadotropin. J Clin Endocrinol Metab 1980; 51: 35-40.
44. Mulligan T et al. Amplified nocturnal luteinizing-hormone (LH) secretory burst frequency with selective attenuation of pulsatile (but not basal) testosterone secretion in healthy aged men-possibleLeydig's-cell desnzitiuation to endogenous LH signaling-a clinical research-center study. J Clin Endocrinol Metab 1995; 80: 3025-3031.
45. Leifke E et al. Age-related changes of serum sexhormones, insulin-like growth factor I and sex-hormone binding globulin levels in men: Cross-sectional data from a healthy male cohort. Clin Endocrinol 2000; 53: 689-695.
46. Krithivas K et al. Evidence that CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J Endocrinol 1999; 162: 137-142.
47. Ukkola O et al. Age, body mass index, race and another determinants of steroid hormone variability: The HERITAGE Family Study. Eur J Endocrinol 2001; 145: 1-9.
48. Bacarelli A et al. Activin A serum levels and aging of the pituitary-gonadalaxis: A cross-sectional study in middle-aged and elderly healthy subjects. Exp Gerontol 2001; 36: 1403-1412.
49. Kosasih JB, Abbasi AA, Rudman D. Serum insuline-like growth factor-I and serum testosterone status of elderly men in an inpatient rehabilitation unit. Amer J Med Sci 1996; 311: 169-173.
50. Brinkley N et al. Clinical prediction of testosterone deficiency in male nursing home residents. Nurs Home Med 1995; 3: 295-299.
51. Barret-Connor E, Goodman Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 1999; 84: 3681-3685.
52. English KM et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000; 21: 890-894.
53. Silber SJ. Effects of age on male fertility. Semin Reprod Endocrinol 1991; 9: 241-248.
54. McKinlay JD, Feldman MA. Age related variation in sexual activity and interest in normla men: Results of the massachussets Male Anging Study. In: Rossi AJ (Ed). Sexuality across the Life Course. Chicago, IL: The University of Chicago Press, 1994: 213-236.
55. Morley JE. Impotence. Amer J Med 1986; 80: 897-906.
56. Billington CJ et al. Testosterone therapy in impotent patients with normal testosterone. Clin Res 1983; 31: 718A.
57. Nankin HR, Lin T, Osterman J. Chronic testosterone cypionate therapy in men with secondary impotence. Fertl Steril 1986; 300-307.
58. Morley JE et. al. Validation of a screening questionnaire for androgen deficiency in aging males. Metab 2000; 49: 1239-1242.
59. Morales A et al. Testosterone supplementation for hypogonadal impotence: Assessment of biochemical measures and therapeutic outcomes. J Urol 1997; 157: 849-854.
60. Kunelius P et al. The effects of transdermal dihydrotestosterone in the aging male: A prospective, randomized, double mind study. J Clin Endocrinol Metab 2002; 87: 1467-1472.
61. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092-1098.
62. Sih R et al. Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial. J Clin Endocrinol 1997; 82: 1661-1667.
63. Yue P et al. Testosterone relaxes rabbit coronary arteries and aorta. Circulation 1995; 91: 1154-1160.
64. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092-1098.
65. Bhasin S et al. The effects of supraphysiological doses of testoste rone on muscle sizr and strength in normal men. New Engl J Med 1996; 335: 1-7.
66. Meikle AW. A permeation enhanced non scrotal testosterone trans-dermal system for the treatment of male hypogonadism. In: Nieschlag E, Behre HD, editors. Testosterone, Action, Deficiency, Substitution. Berlin: Springer, 1997: 390-422.
67. Gooren LJG. A ten year safety study of the oral androgen, testoste-roneundecanoate. Amer Soc Androl 1994; 15: 212-215.
68. Tangredi JF, Buxton IL. Hypertension as a complication of topical testosterone therapy. Ann of Pharmacol 2001; 35: 1205-1207.
69. Sandblom RE et al. Obstructive sleep apnea syndrome induced by testosterone administration. N Engl J Med 1983; 308: 508-510.
70. Dale M, Ahrendt MD. Ergogenic Aids: Counseling the Athlete. Amer Fam Physicians, 2001; 63: 913-922.
71. Ondrusová M, Ondrus D, Dusek L, Spanikova B. Damage of hormonal function and bone metabolism in long-term survivors of testicular cancer. Neoplasma 2009; 56 (6): 473-479.